what are the risks of glp-1 drugs Part 2 a 3-Part Series; Medications for Weight Loss what are the side effects

Glatter: In practice, many patients labeled non-responders to GLP-1 therapy are experiencing incomplete dosing, early discontinuation because of gastrointestinal side effects, insufficient treatment duration, or competing metabolic drivers such as severe insulin resistance, sleep disruption, sarcopenia, or medication-associated weight gain

References Bray GAPJ

Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain

95% CI, 0.78-0.97)

However, theres some evidence from other federal agencies that adult obesity rates rose even higher during the pandemic

Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al